- Home
- MNPR vs RENB Comparison
MNPR vs RENB Comparison
Compare MNPR & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- RENB
- Stock Information
- Founded
- MNPR 2014
- RENB 2011
- Country
- MNPR United States
- RENB United States
- Employees
- MNPR N/A
- RENB N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- RENB Health Care
- Exchange
- MNPR Nasdaq
- RENB Nasdaq
- Market Cap
- MNPR 113.5M
- RENB 121.3M
- IPO Year
- MNPR 2019
- RENB N/A
- Fundamental
- Price
- MNPR $28.54
- RENB $0.71
- Analyst Decision
- MNPR Strong Buy
- RENB
- Analyst Count
- MNPR 4
- RENB 0
- Target Price
- MNPR $38.50
- RENB N/A
- AVG Volume (30 Days)
- MNPR 59.4K
- RENB 1.8M
- Earning Date
- MNPR 11-08-2024
- RENB 02-12-2025
- Dividend Yield
- MNPR N/A
- RENB N/A
- EPS Growth
- MNPR N/A
- RENB N/A
- EPS
- MNPR N/A
- RENB N/A
- Revenue
- MNPR N/A
- RENB N/A
- Revenue This Year
- MNPR N/A
- RENB N/A
- Revenue Next Year
- MNPR N/A
- RENB N/A
- P/E Ratio
- MNPR N/A
- RENB N/A
- Revenue Growth
- MNPR N/A
- RENB N/A
- 52 Week Low
- MNPR $1.55
- RENB $0.40
- 52 Week High
- MNPR $38.50
- RENB $5.25
- Technical
- Relative Strength Index (RSI)
- MNPR 60.16
- RENB 38.93
- Support Level
- MNPR $24.00
- RENB $0.74
- Resistance Level
- MNPR $26.52
- RENB $0.94
- Average True Range (ATR)
- MNPR 2.42
- RENB 0.14
- MACD
- MNPR 0.32
- RENB -0.04
- Stochastic Oscillator
- MNPR 68.85
- RENB 1.21
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.